AI new drug development specialist Syntekabio announced on the 7th that it successfully promoted its AI new drug platform to attract new clients by participating in the Bio International Convention 2024 (BioUSA).
At this event, Syntekabio set up a standalone promotional booth measuring 56㎡ (17 pyeong) and held partnering meetings with over 40 global pharmaceutical companies and biotech firms over four days. On the first day of the event, an unusually large number of visitors crowded the booth, drawing significant attention from industry insiders to Syntekabio’s AI new drug platform. In addition to the partnering event, the company conducted consultations with hundreds of companies at the booth throughout the event, receiving great responses.
Syntekabio focused on promoting its key services and platforms. The STB LaunchPad service, a database (DB) of effective substances derived in advance, the AI new drug platform ‘DeepMatcher®’, the neoantigen prediction platform ‘NEO-ARS®’ applicable to cancer vaccine development, and ‘Ab-ARS™’ for antibody drugs attracted attention.
The STB LaunchPad service allows new drug development to start based on a database of effective substances that have been derived and experimentally validated in advance, contributing to shortening the new drug development period and accelerating development speed. This guarantees the discovery of effective substances for desired targets.
Many potential clients interested in new drug development showed great interest in the fact that this platform enables development from synthetic drugs to biopharmaceuticals. They were also interested in Syntekabio’s capability to discover and optimize drugs within its AI supercomputer infrastructure and cloud environment, which it has built in-house, expanding from synthetic drugs to cancer vaccines and antibody drugs. The company plans to conduct follow-up meetings with the companies connected through BioUSA and turn these into business achievements.
The company expects that the proportion of biopharmaceuticals in the global pharmaceutical market will continue to expand and grow in the future, and thus demand for biopharmaceutical development in the AI new drug development field will increase. During one-on-one meetings, clients showed high interest in biopharmaceutical platforms such as neoantigen and antibody prediction.
Jung Jong-sun, CEO of Syntekabio, said, “We could feel that industry interest in cloud supercomputer-based AI new drug development platforms has increased compared to last year,” adding, “This was the most active business meeting among the global partnering events we have participated in so far, and we received many inquiries.”
He continued, “With the successful conclusion of this event, we plan to further expand our global client base through follow-up meetings.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
